Potent and cell permeable ATP competitive JNK inhibitor (hJNK1: IC50=150nM, hJNK2: IC50=220nM and hJNK3: IC50=70 nM). Displays anti-inflammatory properties and has been shown to reduce TNF-α plasma levels induced by LPS in mice.
Product Details
| Alternative Name: | 1,3-Benzothiazol-2-yl-(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl) acetonitrile, JNK Inhibitor V |
| |
| Formula: | C20H16N6S |
| |
| MW: | 372.5 |
| |
| CAS: | 345987-15-7 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Purity Detail: | Sum of two isomers. |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | White to yellow solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stock solutions are stable for up to 3 months when stored at -20°C. |
| |
| Handling: | Hygroscopic. Packaged under inert gas. Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
EPA Prevents the Development of Abdominal Aortic Aneurysms through Gpr-120/Ffar-4: R. Kamata, et al.; PLoS One
11, e0165132 (2016),
Application(s): Cell culture, Mouse aortic SMCs ,
Abstract;
Full Text
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase: P. Gaillard, et al.; J. Med. Chem.
48, 4596 (2005),
Abstract;
AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties: S. Carboni, et al.; J. Pharmacol. Exp. Ther.
310, 25 (2004),
Abstract;
Full Text
